Neoadjuvant Treatment of Neuroendocrine Cervix Carcinomar With Camrelizumab Combined With Etoposide and Cisplatin

Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexFemale
Age18-75
SponsorFujian Cancer Hospital

About this trial

This study is a single arm, exploratory clinical study aimed at evaluating the efficacy and safety of karelizumab combined with etoposide and cisplatin in the neoadjuvant treatment of neuroendocrine cervix carcinoma.

Eligibility criteria

Qualifiers

The blood routine test must meet the following criteria: (no blood transfusion within 14 days)

HB ≥ 100g/L

WBC ≥ 3 × 109/L

ANC ≥ 1.5 × 109/L

Disqualifiers

Those who have a history of chemotherapy, radiation therapy, targeted drug therapy, or immunotherapy in the past.

Patients who have Contraindication to surgical treatment and chemotherapy or whose physical condition and organ function do not allow large abdominal surgery.

Distant metastasis.

Have any active autoimmune disease or history of autoimmune disease (such as interstitial pneumonia, Uveitis, enteritis, hepatitis, hypophysitis, Vasculitis, Myocarditis, nephritis, Hyperthyroidism, hypothyroidism, including but not limited to these diseases or syndromes); Except for Vitiligo or recovered childhood asthma/allergy patients who do not need any intervention after adulthood; Autoimmune mediated hypothyroidism treated with stable doses of thyroid replacement hormone; Type I diabetes with a stable dose of insulin.

Trial design

Treatments tested in this trial

  • Karelizumab combined with etoposide and cisplatin

Treatment groups

30 Participants
are divided into 1 treatment group

Sponsors and collaborators